SELENOP and diabetes mellitus: Regarding glucose tolerance in muscles, adenosine monophosphate-activated protein kinase (AMPK) is a mediator in the regulatory activity of SELENOP, so this fact considers SELENOP a future therapeutic target in diabetes mellitus 2 types [224].